|
| |
InNexus Biotechnology, Inc.approaches that add secondary properties to monoclonal antibodies (binding is a primary property) and applies to virtually every antibody product currently in development. Adding these secondary properties can increase the potency of antibodies or add new properties such as the ability to penetrate into living cells.
As an example, InNexus utilized SAT with a humanized monoclonal antibody, licensed by the FDA for the treatment of non-Hodgkin’s, B-Cell lymphoma. SAT greatly enhanced the killing of cancer cells in culture by this antibody, dramatically increasing its potential potency
| Contact Details: |
| 13208 East Shea Boulevard, Suite 200The Mayo Clinic MCCRB Building |
| Scottsdale |
| Arizona |
| 85259 |
| United States of America |
| Tel: | |
| Fax: | 1-425-696-0068 |
| Email: | business@innexusbiotech.com |
| WWW: | www.INNEXUSBIOTECH.COM/
|
|
Loading...
|
Press Releases on InNexus Biotechnology, Inc.:
|
 |
| AACR 100th Annual Meeting Highlights Superior Ability of InNexus' DXL-Modified Anti-CD20 Antibody to Attach and Kill NHL With Safety Comparable to Approved Antibody Therapies in Preclinical Studies |
20th April, 2009 |
|
DENVER, April 20 /PRNewswire/ -- DXL625 monoclonal antibodies appear to be superior to commercial-stage
antibodies in their ability to attach and deplete NHL in late stage
pre-clinical studies,
|
| AACR Data Highlights InNexus Preclinical Antibody Candidate |
9th April, 2009 |
|
SCOTTSDALE, Arizona, April 9 /PRNewswire/ -- InNexus Biotechnology Inc. (Toronto Stock Exchange: IXS.V,
http://www.ixsbio.com), a drug development company commercializing the next
generation of
|
| InNexus Biotechnology Announces a Loan Facility of up to USD$2.5 Million |
25th March, 2009 |
|
BRITISH COLUMBIA, Canada, March 25 /PRNewswire/ -- InNexus Biotechnology Inc., (OTC Bulletin Board: IXSBF; TSX VENTURE: IXS;
http://www.ixsbio.com), a drug development company commercializing the next
|
| InNexus Biotechnology Announces New Patents Protecting Novel Cell Penetrating DXL(TM) Antibodies |
6th March, 2009 |
|
BRITISH COLUMBIA, Canada, March 6 /PRNewswire/ -- InNexus Biotechnology Inc. (OTC Bulletin Board: IXSBF; TSX VENTURE: IXS;
http://www.ixsbio.com), a drug development company commercializing the next
|
| FDA Provides A Positive Review of InNexus Biotechnology Development Plan for Lead Product |
3rd March, 2009 |
InNexus Biotechnology Inc. |
- Agency Supports Company's Production and Clinical and Preclinical Plans for DXL625 -
- Live Teleconference Scheduled with Leadership and Scientific Team for March 04, 2009 -
BRITISH COLUMBIA,
|
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 329 times since April 2007, the link to the organisation's website has been followed 60 times Search for more companies in Scottsdale Search for more companies in Arizona This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for InNexus Biotechnology, Inc. |
